Key Highlights

  • The offering priced each unit, consisting of one share and one warrant, at $0.71 per share.
  • Net cash after placement fees and expenses amounted to approximately $3.335 million.
  • Maxim Group LLC received a cash fee equal to 6.25% of proceeds, totaling $260,000, plus a $100,000 reimbursement.
  • Placement agent warrants covering 225,320 shares (4.0% of the offering) carry a $0.71 exercise price.

AETHLON MEDICAL Inc. (NASDAQ: AEMD) disclosed that its recent financing closed on July 7, 2026. The transaction combined the sale of common stock and associated warrants at a unified price of $0.71 per share, generating gross proceeds of about $4,000,000 million before fees.

Offering Structure

The deal was structured as a unit offering, each unit comprising one common share or a pre‑funded warrant together with a common warrant.

Pricing Mechanics

Nasdaq rule 5635 defines a minimum price requirement for such offerings. The pricing satisfied the rule by exceeding the baseline minimum plus an additional $0.125 per share, ensuring no additional shareholder approval was necessary for the issuance.

Placement Agent Compensation

Maxim Group LLC acted as the placement agent on a best‑efforts basis. The firm earned a cash fee calculated at 6.25% of the total proceeds, which amounts to $260,000, and received a reimbursement of $100,000 for allowable expenses. In addition, Maxim was granted 225,320 warrants to purchase up to 225,320 shares of common stock, representing 4.0% of the shares placed in the offering.

Proceeds Allocation

After accounting for the placement agent’s cash fee and expense reimbursement, AETHLON MEDICAL retained roughly $3.335 million in net cash. Management indicated the funds will be applied to working capital and general corporate purposes, supporting ongoing operations and development initiatives.

Shareholder Restrictions

The agreement includes a 90‑day prohibition on issuing additional equity or equivalents, and a one‑year restriction on variable‑rate transactions without Maxim’s written consent. Executives and directors also entered lock‑up agreements, limiting any sale of their holdings for the same 90‑day period.

Regulatory Timeline

The registration statement (Form S‑1, File No. 333- 296933) was first filed on June 22, 2026, amended on July 1, 2026, and declared effective by the SEC on July 6, 2026. The offering closed the following day, completing the capital raise under the stipulated terms.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.